MedTrace Logo

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

NCT04440267 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-08-06

No results posted yet for this study

Summary

In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) after CR . Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. The purpose of current study is to evaluate the clinical efficacy of ALL-based chemotherapy，effect of genetic abnormality and minimal residual disease (MRD) on prognosis in patients with acute leukemia of ambiguous lineage.

Conditions

  • Acute Leukemia of Ambiguous Lineage

Interventions

DRUG

vincristine

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

daunorubicin

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

cyclophosphamide

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

L-Asparaginase

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

prednisone

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

mercaptopurine

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

methotrexate

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

dexamethasone

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

Tyrosine kinase inhibitor

acute lymphoblastic leukemia (ALL) -based chemotherapy

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2026-06-20
Completion
2027-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04440267 on ClinicalTrials.gov